Michael Oredsson to leave Probi – Gun-Britt Fransson new interim CEO

Michael Oredsson will leave as CEO of Probi to take up a position as CEO at listed pharmaceutical company BioInvent. Probi’s VP R&D Gun-Britt Fransson has been appointed interim CEO. Michael Oredsson will remain at the disposal of Probi  until he takes up his new position.

”The Board wants to thank Michael for an excllent contribution since he joined the company in 2007. Under Michaels leadership, Probi’s revenue has grown from just under MSEK 40 to MSEK 100 whilst establishing robust profitability. We will now recruit a person whose main task will be to continue Probi´s international expansion and broadening of activities with a strenghtened focus on R&D” says Per Lundin, Probi’s Chairman .

Gun-Britt Fransson has been VP R&D at Probi since February 2012. She has held leading postions in the biotech and food industries during the past twenty years. Before she joined Probi, Gun-Britt was CEO at Alligator Bioscience AB in Lund. Prior to that, she was R&D Director at Procordia Foods AB and Orkla Foods A.S.

This information is in a category which should be made public by Probi AB under the provisions of the Securities Market Act and/or the Financial Instruments Trading Act. 

Per Lundin, chairman Probi, mobile +46 705 74 11 71, e-mail: per.lundin@transit.se
Gun-Britt Fransson, VP R&D Probi, tel: +46-286 89 74, mobile: +46 705 95 73 27, e-mail: gun-britt.fransson@probi.se

Probi is a leading player in probiotic research and development of effective and well-documented probiotics. The research areas are: the gastrointestinal tract, immune system, metabolic syndrome and stress and recovery. Probi’s customers are leading companies in the Functional Food and Consumer Healthcare segments. Total income for 2012 was MSEK 100.4. Probi’s share is listed on Nasdaq OMX Stockholm, Small Cap. Probi has approximately 5,000 shareholders. Read more on www.probi.se. 


About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.


Documents & Links